Literature DB >> 12438227

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

John J Gildea1, M Jabed Seraj, Gary Oxford, Michael A Harding, Garret M Hampton, Christopher A Moskaluk, Henry F Frierson, Mark R Conaway, Dan Theodorescu.   

Abstract

To discover novel metastasis suppressor genes that are clinically relevant in common human cancers, we used isogenic human bladder cancer cell lines and used DNA microarray technology to identify genes whose expression diminishes as a function of invasive and metastatic competence. We then evaluated the expression profile of such genes in 105 pathologically characterized tumors from seven common organ sites, and we identified one gene, RhoGDI2, whose expression was diminished as a function of primary tumor stage and grade. When RhoGDI2 was transferred back into cells with metastatic ability that lacked its expression, it suppressed experimental lung metastasis but did not affect in vitro growth, colony formation, or in vivo tumorigenicity. In addition, RhoGDI2 reconstitution in these cells blocked invasion in an organotypic assay and led to a reduction of in vitro motility. These results indicate that RhoGDI2 is a metastasis suppressor gene, a marker of aggressive human cancer, and a promising target for therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438227

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  95 in total

1.  Sortilin regulates progranulin action in castration-resistant prostate cancer cells.

Authors:  Ryuta Tanimoto; Alaide Morcavallo; Mario Terracciano; Shi-Qiong Xu; Manuela Stefanello; Simone Buraschi; Kuojung G Lu; Demetrius H Bagley; Leonard G Gomella; Katia Scotlandi; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

2.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

3.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

4.  Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

Authors:  Sumit Borah; Linghe Xi; Arthur J Zaug; Natasha M Powell; Garrett M Dancik; Scott B Cohen; James C Costello; Dan Theodorescu; Thomas R Cech
Journal:  Science       Date:  2015-02-05       Impact factor: 47.728

5.  RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells.

Authors:  Takahide Ota; Masayo Maeda; Shiho Sakita-Suto; Xinwen Zhou; Manabu Murakami; Tsutomu Takegami; Masaaki Tatsuka
Journal:  Clin Exp Metastasis       Date:  2006-11-17       Impact factor: 5.150

6.  Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling.

Authors:  Céline DerMardirossian; Gabriel Rocklin; Ji-Yeon Seo; Gary M Bokoch
Journal:  Mol Biol Cell       Date:  2006-08-30       Impact factor: 4.138

7.  Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Authors:  Neveen Said; Henry F Frierson; Marta Sanchez-Carbayo; Rolf A Brekken; Dan Theodorescu
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

8.  Role of transcriptional corepressor CtBP1 in prostate cancer progression.

Authors:  Rui Wang; Irfan A Asangani; Balabhadrapatruni V S K Chakravarthi; Bushra Ateeq; Robert J Lonigro; Qi Cao; Ram-Shankar Mani; Daniel F Camacho; Natalie McGregor; Taibriana E W Schumann; Xiaojun Jing; Radhika Menawat; Scott A Tomlins; Heng Zheng; Arie P Otte; Rohit Mehra; Javed Siddiqui; Saravana M Dhanasekaran; Mukesh K Nyati; Kenneth J Pienta; Nallasivam Palanisamy; Lakshmi P Kunju; Mark A Rubin; Arul M Chinnaiyan; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

9.  RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.

Authors:  Zhong Zheng; Xiang-Yi He; Jian-Fang Li; Bei-Qin Yu; Xue-Hua Chen; Jun Ji; Jia-Nian Zhang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

10.  Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.

Authors:  Steven Christopher Smith; Brian Nicholson; Matthew Nitz; Henry F Frierson; Mark Smolkin; Garret Hampton; Wael El-Rifai; Dan Theodorescu
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.